ArticleJournal of immunology (Baltimore, Md. : 1950)2025
G9a controls plasma cell differentiation through FOXO1 and ETS1 binding site regulatory networks.
Article in Journal of immunology (Baltimore, Md. : 1950), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Isotype-specific antibody secreting plasma cells harbor epigenetic and transcription factor architectures defining distinct cell lineages.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
B cell differentiation is tightly regulated through coordinated changes in metabolism, division, expression of transcription factors, and epigenetic programming mediated by histone modifying enzymes. Here, we examined the role of an epigenetic writer, the histone H3K9 mono and dimethyltransferase G9a, in B cell development and plasma cell (PC) formation in vivo. Utilizing a B cell specific G9afl/flCd19Cre/+ conditional mouse model we found a significant decrease of marginal zone B cells in G9a knockout (KO) mice. When challenged with a T cell-independent antigen LPS, these mice displayed increased frequencies of activated B cells and plasma cells. Compared to control mice, G9a KO activated B cells divided fewer times before expressing the plasma cell marker CD138. RNA-seq and ATAC-seq revealed dysregulation of genes involved in regulating proliferation and PC function. Integrated bioinformatics analyses identified potential transcription factor targets of G9a as FOXO1, ETS1, and ELF1 as their putative target genes were dysregulated, thereby providing a potential mechanism for how these pathways are controlled. Importantly G9a deficiency was associated with genes that were both up and down modulated, highlighting distinct regulatory modes of action. Together, these data show that G9a is critical to the fate and restricts specific aspects of plasma cell formation, providing a unique set of target genes that could be manipulated in therapies aimed at controlling B cell and PC function or formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.